Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Galecto, Inc.

Get SEC filing alerts via email and in your feed for Galecto, Inc.

GLTO

Galecto, Inc.

About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotech developing small molecule therapeutics targeting fibrosis, cancer, and liver diseases. Its core products include GB3226, an AML inhibitor, and GB1211, a galectin-3 inhibitor for oncology and liver conditions. The company focuses on high unmet medical needs, leveraging its expertise in galectin biology to improve treatment options and enhance immunotherapy efficacy.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Galecto, Inc.

1
1
Galecto, Inc. Damora Therapeutics Reports $27.8 Million Net Loss and Increased R&D Expenses in Latest Filing

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Galecto, Inc. Damora Therapeutics Reports $209.8 Million Net Loss and Strategic Acquisition in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Galecto, Inc. Galecto Reports $3.1 Million Net Loss in Q3 2025, Seeks Additional Funding

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Galecto, Inc. Galecto, Inc. Reports $3.4 Million Net Loss in Q2 2025, Focuses on AML Drug Development

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Galecto, Inc. Galecto Reports $2.5 Million Net Loss in Q1 2025, Significant Expense Reductions Noted

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Galecto, Inc. Galecto, Inc. Reports $21.4 Million Net Loss for 2024, Highlights Strategic Acquisition and Operational Changes

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Galecto, Inc. Galecto, Inc. Reports Financial Developments, Restructuring Efforts, and Strategic Shift in Recent 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments